MedTrace Logo

Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC

NCT04459468 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2026-01-08

No results posted yet for this study

Summary

This study will enroll patients with hepatocellular carcinoma being planned for TACE or other standard of care treatment (such as denovo ablation or Y90) and obtain blood samples pre and post treatment procedure for biomarker identification using bead based X-aptamer library. No intervention is planned.

Conditions

Interventions

DRUG

Lipiodol

Lipiodol TACE procedure

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Anil Pillai, M.D. · University of Texas Southwestern Medical Center

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-04
Primary Completion
2025-09-23
Completion
2025-09-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04459468 on ClinicalTrials.gov